The development of China’s vaccine industry in the past decade: the perspective from drug regulatory science
Analysis of the batch issued data of Chinese vaccines from 2011 to 2020 showed that the average annual dose of vaccines in China was 769.66 million doses, and the overall production was stable. Fourteen new vaccines were added, six of which were developed in China. The batch issued dose of national...
Main Authors: | Guanjie Wang, Mingli Shao |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-12-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2021.2002640 |
Similar Items
-
Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders
by: Manuel Wiesinger, et al.
Published: (2017-10-01) -
Decadal Prediction of the Summer Extreme Precipitation over Southern China
by: Huijie Wang, et al.
Published: (2023-03-01) -
Points to consider for COVID-19 vaccine quality control and national lot release in Republic of Korea: focus on a viral vector platform
by: Jung Hun Ju, et al.
Published: (2022-02-01) -
Review on Drug Regulatory Science Promoting COVID-19 Vaccine Development in China
by: Zhiming Huang, et al.
Published: (2022-03-01) -
Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: A randomized, single blind, multicentre, phase IV clinical study
by: Gadey Sampath, et al.
Published: (2017-07-01)